Skip to main content
. Author manuscript; available in PMC: 2014 Jan 31.
Published in final edited form as: J Immunol. 2009 Dec 15;183(12):7799–7809. doi: 10.4049/jimmunol.0900155

FIGURE 6.

FIGURE 6

Addition of CD11b− APCs to an allogeneic graft of HSC and T cells increased leukemia-free survival without increasing GvHD. A, Survival of mice that received various doses (0, 3 × 105, or 3 × 106) of donor splenic T cells and CD11b− or CD11b+ APCs in B6→B10 transplant pair with no leukemia cells (see legend in B). B, Mean GvHD clinical scores in B6→B10 recipients with no leukemia. C, Body weight loss in B6→B10 recipients with no leukemia. D–I, HSCs and 3 × 105 T cell dose groups only. D, Survival of mice in C3H→B6 transplants with no leukemia cells. E, Mean GvHD clinical scores in C3H→B6 recipients with no leukemia cells. F, Body weight loss in C3H→B6 recipients with no leukemia cells. G, Survival of B10 mice that received B6 transplants with 1 × 105 viable LBRM leukemia cells in 5 separate experiments with 10 mice per experimental group. H, The fraction of mice from G with pathological evidence for tumor at necropsy. I, Survival of B6 mice that received C3H.SW transplants with 5 × 104 viable MMB3.19 leukemia cells, in 2 experiments, with 10 mice per experimental group. Arrows,i transplant groups that received CD11b− APC. #, Mice euthanized due to body weight loss were ≥25%. p values (***, p < 0.001) represent log-rank comparison of survival of recipients of CD11b− APCs with recipients of HSCs and T cells.